Placeholder Banner

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

October 1, 2009
XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta (IL-1 beta), XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseases. The clinical trials are designed to further evaluate the use of multiple dose regimens on the safety, pharmacodynamics and efficacy of XOMA 052 in cardiometabolic and other diseases, and based on positive results, select doses for pivotal Phase 3 studies.

Read the release.